MLICM
CRMD icon

Metropolitan Life Insurance Company (MetLife)’s CorMedix CRMD Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio CRMD Stock Details CRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,574
Closed -$6.67K – 507
2024
Q1 		$6.67K Sell
1,574
-882
-36% -$3.06K ﹤0.01% 2225
2023
Q4 		$9.23K Hold
2,456
– – ﹤0.01% 2204
2023
Q3 		$9.09K Hold
2,456
– – ﹤0.01% 2252
2023
Q2 		$9.74K Buy
+2,456
New +$12.2K ﹤0.01% 2311

Other funds holding CRMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EIM
Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s CRMD Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of CorMedix (CRMD) in Q2 2024, closing a stake of 1,574 shares — an estimated $6.67K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in CRMD in Q2 2023 and held it in 4 quarters. The position peaked at $9.74K in Q2 2023. 99 funds tracked by Wall St. Rank hold CRMD as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining CorMedix position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 1,574 CorMedix shares in Q2 2024, an estimated $6.67K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in CorMedix in Q2 2023 and held it in 4 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s CorMedix position peaked at $9.74K in Q2 2023.
  • 99 funds tracked by Wall St. Rank held CorMedix as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.